Independent pharmacy lobbyists renew call for health-reform relief

ALEXANDRIA, Va. Weighing once again into the health-reform fray on Capitol Hill, the National Community Pharmacists Association Wednesday reiterated a long-standing plea to Congress for relief as the U.S. Senate and House work to craft a compromise on the health-reform bill to send to the White House.

The appeal came in a letter, sent by NCPA EVP and CEO Bruce Roberts, to House Speaker Nancy Pelosi, D-Calif., and Senate Majority Leader Harry Reid, D-Nev. Among NCPA’s top priorities: a reasonable minimum payment system for Medicaid prescriptions, new curbs on pharmacy benefit managers and a pass on new Medicare restrictions governing the sale of durable medical equipment and diabetic supplies.

The independent pharmacy lobby is asking the House and Senate leadership to include those elements in a final version of health-reform legislation. Although Congress has yet to reconvene later this month, Pelosi and Reid have maintained a high-profile effort to reconcile the reform bills passed late last year by both houses of Congress.

“Community pharmacists are ready and willing to help improve health outcomes and lower costs,” said Roberts. “We greatly appreciate the bipartisan backing in both chambers for reforms that support community pharmacists.

“The recommendations we present here will make a good thing even better for patients,” he asserted in his appeal to both leaders. “We will continue working with Congress in hopes of enacting these proposals.”

Among NCPA’s specific requests:

A reform of Medicaid’s Average Manufacturer Price (AMP) reimbursement system for generic drugs, and the adoption by Medicaid of the Senate’s proposal for a federal upper limit of no less than 175% of the weighted average AMP. “Anything less could force many independent community pharmacies, which care for an extraordinarily high number of Medicaid patients, out of the program,” noted the group.

The adoption of both House-passed transparency provisions for pharmacy benefit managers operating in the proposed health insurance exchange, and Senate language extending the reporting requirements to Medicare Part D drug plans;

Inclusion of the Senate’s proposal to exempt retail pharmacies from Medicare’s “burdensome, duplicative accreditation requirements” for the sale of durable medical equipment and supplies, including diabetes testing kits.

Roberts also urged Congress to “support all House- and Senate-passed provisions expanding the community pharmacist’s ability to provide medication therapy management services,” according to today’s letter. Pharmacist-administered MTM, he noted, would help “maximize the patient’s adherence and therapeutic benefit while lowering the cost of inappropriate prescription drug use — estimated at $290 billion annually.”

Taro elects directors in shareholders meeting; Sun disapproves

HAWTHORNE, N.Y. An Israeli drug maker said that its shareholders voted to elect all of the directors who were up for election, with the exception of the statutory external directors, at its annual shareholders meeting held Dec. 31.

The shareholders also approved the ratification of indemnification for non-executive directors and the appointment of the Taro’s independent auditors.

The company said that it stands behind its nominees for statutory external directors and their qualifications, and further stated that it would continue its efforts to elect statutory external directors as required by Israeli law, despite the efforts of Sun Pharmaceutical Industries to block their election. Sun has claimed that Barrie Levitt, Taro’s chairman, signed contractual obligation to sell Taro’s shares to Sun at a pre-defined price in June 2008. Sun said, however, that Levitt and the company “have prevented the close of this transaction through improper use of Taro resources.”

Sun has sought to acquire Taro for some time. In August 2008, Sun’s tender offer to acquire the company expired, but said that it would once again seek to acquire Taro. In late September, Taro sued Sun in the U.S. District Court for the Southern District of New York, alleging that Sun failed to disclose information to Taro shareholders, and misappropriating confidential information about Taro as part of its efforts to acquire the company – which it has sought to do since June 2008 – and illegally using it to undermine Taro’s relationships with customers and revenues.

RELATED NEWS

The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.

Behavioral health pharmacy and telepsychiatry company Genoa, a QoL Healthcare Company, has reached a big number with its remote psychiatry offering. The Tukwila, Wash.-based company announced Tuesday that it had facilitated more than 100,000 telepsych consultations on its video conferencing platform.
Genoa attributes the milestone to its recent buildup of its telepsychiatry operations, which grew to include 35 in 2017 from 20 at the start of the year, and included 250 providers. In 2017, the company grew to serve more than 2,500 patients per week.

This year's flu continues to be Texas big, according to the Walgreens Flu Index released Wednesday, as the top 10 communities experiencing the greatest amount of flu incidence were all located in the Lone Star State for the week ended Jan. 6.
Iowa, Idaho and Arkansas rank behind Texas in terms of flu activity. And Montana, Idaho and Iowa ranked highest among states experiencing flu activity gains.

Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.
Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.
The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.

Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. This generic from the Bridgewater, N.J.-based company is an AB-rated therapeutic equivalent to Renvela.
Amneal also launched five other products in addition to sevelamer carbonate:

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry